Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Castle Biosciences (CSTL) stock in plain English

Free brief · no signupStart here
CSTLPublished Nov 18, 2026
Castle Biosciences Inc
Healthcare · Diagnostics & Research
Develops and sells genomic tests that guide treatment decisions for dermatologic cancers and esophageal disease.
Assets:
Two central laboratoriesOperating CLIA-certified testing facilities in Phoenix, Arizona and Pittsburgh, Pennsylvania
DecisionDx-MelanomaProprietary gene expression profile test serving as the primary revenue driver
TissueCypher platformSpecialized precision medicine test predicting progression risk in Barrett esophagus
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

72
OPS ScoreOperating finances
Latest quote
+0.07%$33.40
$1.03B
n/a (loss)
$377.10M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 18, 2026Quotes updated Nov 20, 04:00 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was CSTL. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Castle Biosciences (CSTL) do?

Castle Biosciences Inc (CSTL) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Develops and sells genomic tests that guide treatment decisions for dermatologic cancers and esophageal disease. It is worth $1.03B on the market and sold $377.10M over the last year.

Market cap
$1.03B
P/E ratio
None (reported a loss)
Annual sales
$377.10M
Sector
Healthcare
Industry
Diagnostics & Research
Brief updated
Nov 18, 2026

Brands and businesses behind CSTL

  • DecisionDx-Melanoma: Calculates recurrence risk for cutaneous melanoma patients using tumor biology to earn laboratory diagnostic fees.
  • TissueCypher: Predicts esophageal cancer progression in Barrett esophagus patients to generate specialized diagnostic testing revenue.
  • DecisionDx-SCC: Assesses metastatic risk in cutaneous squamous cell carcinoma patients to earn insurance and Medicare testing reimbursements.
  • IDgenetix: Guides medication selection for depression and anxiety through pharmacogenomic testing to generate diagnostic service revenue.

CSTL’s flags, in plain English

Each flag is a number from Castle Biosciences’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.

Stupid Cash

Can pay this year's bills 5.3 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 8% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 74.1% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Burning Cash

Losing money, profit margin of -6.1%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

1 more green flag and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about CSTL

How big is Castle Biosciences?

Castle Biosciences’ market cap is $1.03B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $377.10M: what customers paid the company over the last year, before any costs.

What is CSTL’s P/E ratio?

CSTL has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with CSTL?

Medicare contractors periodically reevaluate coverage determinations, which creates ongoing reimbursement uncertainty for key diagnostic tests. That is one risk on Castle Biosciences’ card. Its first risk flag is Burning Cash, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Castle Biosciences’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. CSTL’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card